Idhifa (Enasidenib Mesylate) Patent Expiration, LOE Window & CMS Spending
Idhifa (Enasidenib Mesylate) by Bristol Myers Squibb: FDA Orange Book core substance LOE 2034-09-16, 0 AB generics, $196.2M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Bristol Myers Squibb |
| FDA Application & Pathway | N209606 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2034-09-16 |
| Last Listed Patent or Exclusivity Date | 2034-09-16 |
| Orange Book Patents (*PED Extensions) | 6 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $196.2M |
| 2024 Medicare Part D Spend | $184.7M |
| 2024 Medicaid Spend | $11.5M |
| Reported Wholesale Price Change (CA SB 17) | 6 WAC filings (max 22.1% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.